Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

2 Biotech Stock to Buy Over Moderna This December

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

StockNews.com

Moderna mRNA melanoma vaccine may be 'the penicillin moment' in cancer treatment, researchers say

A world-first melanoma vaccine which personalises treatments for patients may put an end to melanoma as a "death sentence", according to Australian experts.

ABC News

Cancer vaccine halves risk of relapse or death using Covid jab technology

Jab led to reduction in risk of cancer coming back or death in patients with stage three and four melanoma

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Has Moderna successfully developed a personalised vaccine against melanoma? Maybe

Moderna has partnered with another drug company to produce a personalised vaccine against melanoma for people at risk of dying.

The New Daily

Skin cancer vaccine trial shows promising results

Moderna and Merck team up in new study.

Fortune

Researchers from Moderna and Merck just made a breakthrough with a skin cancer vaccine

Thank you, science.

Mic

Merck, Moderna detail potential skin cancer vaccine progress

Shares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

The FDA clears updated COVID-19 vaccines for kids under age 5

The decision aims to better protect the littlest kids amid an uptick in COVID-19 cases around the country. The Centers for Disease Control and Prevention is expected to sign off soon.

WEKU

Work starts on nation-first mRNA facility

Biotech giant Moderna's first mRNA vaccine facility in Australia is due to open in 2024, and will produce 100 million vaccine doses per year.

AAP

The business of clinical trials is booming. Private equity has taken notice

After finding success investing in the more obviously lucrative corners of American medicine — like surgery centers and dermatology practices — private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.

Tribune News Service

Former vaccines chief sounds warning about UK pandemic readiness

Kate Bingham raises concerns to committee of MPs as head of UKHSA suggests Covid could be on rise again

The Guardian - UK

Racing to develop Africa’s next-gen vaccines before new pandemic

How scientists across Africa plan to use mRNA technology to fight diseases and tackle inequities in global health.

Al Jazeera

Universal flu vaccine could be ready for human use in two years – expert

The US researchers have created a vaccine based on the same mRNA technology used in the Covid-19 jabs from Moderna and Pfizer.

The Independent UK

Researchers test mRNA technology for universal flu vaccine

An experimental vaccine provided broad protection against all 20 known influenza A and B virus subtypes in initial tests in mice and ferrets, potentially opening a pathway to a universal flu shot that might help prevent future pandemics, according to a U.S. study published on Thursday.

Reuters

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

US renews push for COVID boosters as data show they protect

Americans who have gotten the updated COVID-19 boosters appear better protected against symptomatic infection than those who haven't — at least for now

The Conversation

RSV: experts explain why rates of this virus are surging this year

Respiratory syncytial virus (RSV) is a very common virus, typically causing infection in children during the colder months. In most cases, RSV causes a mild illness, with symptoms similar to that of a regular cold.

The Independent UK

Pfizer booster spurs immune response to new omicron subtypes

Pfizer said its updated COVID-19 booster may offer some protection against newly emerging omicron mutants even though it’s not an exact match

Tribune News Service

Moderna’s bivalent shot boosts antibodies against latest omicron strains in trial

Moderna Inc.’s booster shot of its bivalent vaccine sharply increased antibody levels against recent COVID-19 strains when compared to a fourth dose of its original immunization.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Lordstown Motors, eBay And 2 Other Stocks Insiders Are Selling

The Nasdaq Composite jumped over 750 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Tribune News Service

Pfizer’s COVID cash powers a ‘marketing machine’ on the hunt for new supernovas

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions.

ABC News

Vulnerable Australians want access to another booster dose. Here's the state of play across the country

As COVID cases rise across the country, there are calls for additional booster doses to be made available to Australians who want it.

Fortune

Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortune

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Benzinga

Gold Drops Over 1%; Moderna Reports Downbeat Q3 Results

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday.

The Guardian - US

The ProPublica-Vanity Fair report on Covid’s origins is explosive. Is it reliable?

Critics say the article is flawed. But that shouldn’t discredit the lab leak theory

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Centers for Disease Control and Prevention

314 stories

Merck

292 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.